Literature DB >> 23685544

Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.

F Milat1, S Goh, L U Gani, C Suriadi, M T Gillespie, P J Fuller, H J Teede, A H Strickland, C A Allan.   

Abstract

Prostate cancer is a leading cause of cancer death, frequently associated with widespread bone metastases. We report two cases of hypocalcemia following the first dose of denosumab in metastatic hormone refractory prostate cancer, the first case requiring 26 days of intravenous calcium therapy. This is the first report of prolonged hypocalcemia following denosumab in a patient with normal renal function. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23685544     DOI： 10.1016/j.bone.2013.04.012

Source DB:  PubMed          Journal:  Bone        ISSN： 1873-2763            Impact factor:   4.398


  10 in total

Review 1.  Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?

Authors:  Simon P Gampenrieder; Gabriel Rinnerthaler; Richard Greil
Journal:  Breast Care (Basel)       Date:  2014-10       Impact factor: 2.860

2.  Severe hypocalcaemia as a cause of seemingly idiopathic bilateral lower limb oedema.

Authors:  Aaron Karnell Dachuan Hung
Journal:  BMJ Case Rep       Date:  2014-01-10

Review 3.  Side effects of bone-targeted therapies in advanced breast cancer.

Authors:  Christoph Domschke; Florian Schuetz
Journal:  Breast Care (Basel)       Date:  2014-10       Impact factor: 2.860

4.  Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome.

Authors:  H Shafqat; K F Alquadan; A J Olszewski
Journal:  Osteoporos Int       Date:  2013-10-25       Impact factor: 4.507

5.  Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.

Authors:  Karen A Autio; Azeez Farooki; Ilya G Glezerman; Amelia Chan; Coursen W Schneider; Hallie C Barr; Brian M Seyboth; Lewis J Kampel; Daniel C Danila; Dana E Rathkopf; Susan F Slovin; Howard I Scher; Michael J Morris
Journal:  Clin Genitourin Cancer       Date:  2014-11-22       Impact factor: 2.872

6.  A Case of Recurrent Severe Hypocalcemia with Prolonged Hospitalization and Readmissions After Single Dose of Denosumab in Metastatic Prostate Cancer Patient.

Authors:  Ojbindra Kc; Punya Hari Dahal; Manisha Koirala; Chandra Sekhar Kothagundla; Enas Al Zaghal; Rabih Fahed
Journal:  J Community Hosp Intern Med Perspect       Date:  2022-04-12

7.  The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases.

Authors:  Breanne Lechner; Carlo DeAngelis; Noreen Jamal; Urban Emmenegger; Natalie Pulenzas; Angie Giotis; Parker Sheehan; May Tsao; Gillian Bedard; Edward Chow
Journal:  Support Care Cancer       Date:  2014-02-11       Impact factor: 3.603

8.  Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.

Authors:  Sakura Iizumi; Tatsunori Shimoi; Tadaaki Nishikawa; Atsuko Kitano; Shinsuke Sasada; Akihiko Shimomura; Emi Noguchi; Mayu Yunokawa; Kan Yonemori; Chikako Shimizu; Yasuhiro Fujiwara; Kenji Tamura
Journal:  Intern Med       Date:  2017-09-25       Impact factor: 1.271

Review 9.  Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.

Authors:  Jean-Jacques Body; Roger von Moos; Daniela Niepel; Bertrand Tombal
Journal:  BMC Urol       Date:  2018-09-20       Impact factor: 2.264

10.  A DRAMATIC RESPONSE TO DENOSUMAB: PROTRACTED HYPOCALCEMIA RELATED TO HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE 1-ASSOCIATED ADULT T-CELL LEUKEMIA/LYMPHOMA.

Authors:  Emily Anne Japp; Michal Kasher Meron; Joel Zonszein
Journal:  AACE Clin Case Rep       Date:  2019-04-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.